Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE208443 | GEO | 2023/07/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ChIP-Seq)

Project description:genome-wide mapping of H3K36me3 histone mark in the MDA-MB-231 cell line

2023-07-25 | GSE208442 | GEO

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ATAC-Seq)

Project description:mapping of chromatin accessibility in MDA-MB-231 cells in presence and absence of Fra-1 by ATAC-seq experiments

2023-07-25 | GSE208441 | GEO

Identifying survival associated morphological features of triple negative breast cancer using multiple datasets.

Project description: Not available

| S-EPMC3721170 | biostudies-literature

Blocking Fra-1 sensitizes triple-negative breast cancer to olaparib

Project description:Fra-1 (FOSL1) is overexpressed in triple-negative breast cancer (TNBC). Fra-1 is a member of the activator protein 1 (AP-1) transcription factor complex, which plays crucial roles in tumor progression and treatment resistance. We have previously identified 118 proteins that interact with endogenous chromatin-bound Fra-1 in TNBC cells in a large screen, and these included PARP1(Poly (ADP-ribose) polymerase 1). PARP1 inhibitor olaparib is currently in clinical use for treatment of BRCA-mutated TNBC breast cancer. Here, we demonstrate that this interaction impacts the efficacy of olaparib treatment. We corroborate that PARP1 interacts with Fra-1, and we show that PARP1 downregulates Fra-1 and consequently reduces AP-1 transcriptional activity. Inhibition of PARP1, on the other hand, increases Fra-1 levels and enhances its transcriptional activity, which in turn can increase treatment resistance. However, by inhibiting Fra-1, we found that TNBC cells became sensitized to olaparib treatment. We compared Fra-1 chromatin binding sites with the Fra-1 and PARP1 regulated transcriptomes, and found that a large fraction of PARP1-regulated genes was dependent on Fra-1. We further show that PARP1 protein levels significantly correlate with Fra-1 in clinical breast cancer tumors, and we identify that high PARP1 expression is indicative of a poor clinical outcome in breast cancer patients overall, but not in basal-like tumors. In conclusion, by exploring the functionality of the Fra-1 and PARP1 interaction, we propose that targeting Fra-1 could serve as a therapeutic approach to improve olaparib treatment outcome for TNBC patients.

2022-04-21 | GSE149621 | GEO

Transcriptional regulation by Fra-1 in triple negative breast cancers

Project description:This SuperSeries is composed of the SubSeries listed below. All the data are described in the article "Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers" by Bejjani et al.

2021-02-23 | GSE146825 | GEO

MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.

Project description: Not available

| S-EPMC5519193 | biostudies-literature

Prediction of promoters and enhancers using multiple DNA methylation-associated features.

Project description: Not available

| S-EPMC4474542 | biostudies-literature

Tissue-specific transgenic knockdown of Fos-related antigen 2 (Fra-2) expression mediated by dominant negative Fra-2.

Project description: Not available

| S-EPMC87005 | biostudies-literature

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.

Project description: Not available